Why are the client’s depressive symptoms better controlled with twice‑weekly Spravato (esketamine) treatment rather than once‑weekly dosing?

Why Twice-Weekly Spravato Works Better Than Once-Weekly

Your client's symptoms are better controlled with twice-weekly Spravato because the evidence demonstrates that twice-weekly dosing during the induction phase (first 4 weeks) produces superior antidepressant effects and remission rates compared to less frequent dosing, and some patients require this higher frequency even during maintenance to prevent symptom worsening.

Evidence-Based Dosing Framework

Induction Phase Requirements

The FDA-approved dosing schedule and clinical trial data clearly establish that twice-weekly administration is the standard induction regimen for weeks 1-4 1. This frequency is not arbitrary—a meta-analysis of 5 RCTs found that twice-weekly esketamine dosing as augmentation to oral antidepressants improved depressive symptoms and remission rates in patients with treatment-resistant depression (TRD) at up to 28 days of follow-up 2.

Why Some Patients Need Continued Twice-Weekly Dosing

The key insight is that treatment frequency must be individualized based on symptom response, not simply reduced according to a fixed schedule. Analysis of Phase 3 data reveals critical patterns 3:

• When patients on weekly maintenance dosing had their frequency reduced to every-other-week, 32% experienced symptom worsening
• Conversely, when patients who worsened after frequency reduction had their dosing increased back from every-other-week to weekly, 47% improved
• Among responders maintained on weekly dosing, 50% maintained clinical benefit while 24% worsened

This demonstrates that esketamine's antidepressant effects are frequency-dependent, and the therapeutic window varies substantially between individuals.

Pharmacological Rationale

Short Duration of Action

Unlike traditional antidepressants that maintain steady-state plasma levels, esketamine has a relatively short half-life. The antidepressant effects from ketamine (the racemic mixture) persist for approximately 7 days when added to ongoing antidepressant treatment, but show no significant differences at 7 days when used as monotherapy 2.

This pharmacokinetic profile explains why more frequent dosing maintains therapeutic benefit—the neuroplastic and synaptic changes induced by NMDA receptor modulation require repeated stimulation to sustain antidepressant effects.

Dose-Frequency Relationship

A double-blind study comparing twice-weekly versus thrice-weekly intravenous ketamine found both regimens similarly maintained antidepressant efficacy over 15 days, with mean MADRS reductions of -18.4 for twice-weekly and -17.7 for thrice-weekly dosing 4. This suggests a threshold frequency exists below which therapeutic effects diminish.

Clinical Algorithm for Frequency Optimization

For your client specifically:

1. If currently in weeks 1-4 (Induction): Twice-weekly dosing (56 mg or 84 mg) is the evidence-based standard and should be maintained 1

2. If in weeks 5-8 (Early Maintenance): Transition to once-weekly is protocol-driven, but monitor closely for symptom worsening

3. If beyond week 8 with symptom worsening on once-weekly:

   • Return to twice-weekly dosing immediately 1
   • This is explicitly supported by FDA labeling: "For patients who miss treatment session(s) during maintenance treatment and have worsening of depression symptoms, per clinical judgement, consider returning to the previous dosing schedule" 1

4. Long-term maintenance: Real-world data from up to 260 weeks of treatment shows that dosing patterns evolve from induction to individualized maintenance schedules, with some patients requiring more frequent dosing indefinitely 5

Common Pitfalls to Avoid

Do not rigidly adhere to the protocol schedule of reducing frequency if symptoms worsen. The FDA label explicitly allows for individualized dosing: "Dosing frequency should be individualized to the least frequent dosing to maintain remission/response" 1. The Phase 3 analysis confirms that approximately one-quarter of patients worsen when frequency is reduced 3.

Monitor for symptom changes 4 weeks after any frequency adjustment, as this is the timeframe used in clinical trials to assess response to frequency changes 3.

Ensure adequate monitoring: Each session requires 2 hours of post-administration observation, blood pressure monitoring at 40 minutes, and assessment of respiratory status 1. The logistical burden of twice-weekly visits is substantial but necessary for treatment efficacy and safety.

Supporting Evidence for Sustained Benefit

Long-term data extending up to 4.5 years demonstrates that improvement in depression ratings generally persists among patients who remain in maintenance treatment, with 35.6% in remission at induction endpoint and 46.1% at optimization/maintenance endpoint 6. Mean MADRS scores decreased from 40.0 at baseline to 9.70 at week 52 in real-world cohorts 5.

The bottom line: Your client's better symptom control with twice-weekly dosing reflects the pharmacodynamic reality that esketamine's rapid-acting antidepressant effects require sufficient dosing frequency to maintain neuroplastic changes. This is not treatment failure—it is appropriate individualization of therapy based on clinical response, fully supported by both FDA labeling and clinical trial evidence.